[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients

Janssen, Jan-Carlo; Woythal, Nadine; Meißner, Sebastian; Prasad, Vikas; Brenner, Winfried; Diederichs, Gerd; Hamm, Bernd; Makowski, Marcus R.

doi:10.1007/s11307-017-1101-y

Cited by 25 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the mTOR and AKT signaling pathways were suppressed by exosomes from PC-3 cells. Combining these results and the previous findings that osteoblastic bone metastases in prostate cancer are caused by tumor-derived factors, which lead to osteoblast proliferation, differentiation and bone formation ( 33 ), suggest that prostate cancer bone metastases are mainly osteoblastic ( 34 ). The present study explored whether miR-148a has a role in prostate cancer bone metastases.…”

Section: Discussionsupporting

confidence: 80%

Exosomes derived from PC‑3 cells suppress osteoclast differentiation by downregulating miR‑148a and blocking the PI3K/AKT/mTOR pathway

Tian

Qiu

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Prostate cancer is a leading malignancy in men that can also disrupt the bone tissue balance. Among all urological cancers, prostate cancer is associated with the highest rate of bone metastases, which can greatly reduce a patient's quality of life. In recent years, cell-derived exosomes, which can contain a wide range of biologically active molecules, have been reported as a novel method of communication among individual cells. However, the specific role that exosomes serve in this disease has not been fully elucidated. The prostate cancer cell line PC-3 were applied in the present study, where its exosomes were isolated to explore their potential effects on osteoclast differentiation. Exosomes are extracellular vesicles secreted by cells. The size of exosomes is 30-150 nm. They have double membrane structure and saucer-like morphology. They contain rich contents (including nucleic acid, protein and lipid) and participate in molecular transmission between cells. The combined results of tartrate-resistant acid phosphatase staining (to identify osteoclasts obtained from human peripheral blood mononuclear cells), reverse transcription-quantitative PCR and western blotting showed that PC-3-derived exosomes attenuated osteoclast differentiation by downregulating marker genes associated with osteoclastic maturation, including V-maf musculoaponeurotic fibrosarcoma oncogene homolog B, matrix metalloproteinase 9 and integrin β3. microRNA (miR)-148a expression was also found to be downregulated in osteoclasts by PC-3-derived exosomes. In addition, the mTOR and AKT signaling pathways were blocked after exposure to these PC-3 cell-derived exosomes. Therefore, results from the present study suggest that miR-148a mimics may be a new therapeutic approach for the prevention of prostate cancer bone metastases.

show abstract

Section: Discussionsupporting

confidence: 80%

Exosomes derived from PC‑3 cells suppress osteoclast differentiation by downregulating miR‑148a and blocking the PI3K/AKT/mTOR pathway

Tian

Qiu

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…A single lesion often favors a benign finding, e.g., fibrous dysplasia, which appears as an expansive welldefined lesion with ground-glass attenuation. Benign lesions can also appear as focal mild medullary uptake without any correlated structural bone lesions on CT. On the other hand, PCa metastasis without CT correspondence appears as moderate to high PSMA focal uptake in the bone marrow, often multiple, which is more common in very aggressive disease when the bone destruction has not been demonstrated yet [35]. Faint and heterogeneous PSMA uptake delineating the cortex of pelvic bones is associated with characteristic morphological changes, such as diffuse sclerosis, thickened cortex, bone expansion, and coarsened trabeculae, and is typical for Paget's disease.…”

Section: Bone-related Conditionsmentioning

confidence: 99%

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings

et al. 2020

View full text Add to dashboard Cite

PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the last few years, and a proper interpretation of PSMA PET imaging findings suddenly became challenging and, to some extent, confusing. Compared to cytoplasmic PSMA expression in nonprostatic cells, the molecular features of apical PSMA expression in PCa cells can help to distinguish these various conditions. Correlations of imaging findings to patient history, to the expected pattern of disease spread and mainly to computed tomography (CT) and/or magnetic resonance imaging (MRI) characteristics will reinforce the distinction of lesions that are more likely related to PCa from those that could lead to an incorrect diagnosis. The overall benefits of endothelial PSMA expression, which is associated with the neovasculature of malignant neoplasms, will be highlighted, stating the potential use of PSMA ligand uptake as a theranostic tool. This review aims to cover the collection of nonprostatic diseases, including benign and malignant tumors, in a didactic approach according to disease etiology, with discussion of bone-related conditions and inflammatory and infectious processes.

show abstract

“…PSMA PET has also demonstrated less-known patterns to be far more frequent than previously thought owing to its superior diagnostic power. Lytic and bone marrow metastases, often overlooked, may be found in respectively 13.6% and 19.5% of patients with bone involvement at PSMA PET (67).…”

Section: Comparison Of Psma Pet With Other Imaging Modalitiesmentioning

confidence: 99%

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

et al. 2019

View full text Add to dashboard Cite

The introduction of prostate-specific membrane antigen (PSMA) in clinical practice has revolutionized evaluation of biochemical recurrence of prostate cancer after curative-intent treatment. The high expression of this glycoprotein in prostate cancer cells makes PSMA imaging superior to the current conventional staging methods, namely bone scanning and CT. The high capability of PSMA imaging for identifying very small previously undetected lesions has been widely demonstrated in the literature, leading to a rethinking of patient management by oncologists, urologists, and radiation oncologists. The typical and predictable patterns of spread in prostate cancer are still more prevalent, such as spread to pelvic lymph nodes and bone metastasis, but different patterns of disease spread are becoming more commonly recognized with higher reliability because PSMA imaging allows detection of more typical and atypical lesions than conventional imaging. Furthermore, it is important for the reading physician to recognize and understand the typical disease spread and the most prevalent atypical prostate cancer relapses, not only to heighten the relevancy of reports but also to improve imaging consultancy in multispecialty oncologic practice. ©

show abstract

[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients

Abstract: [Ga]PSMA-HBED-CC uptake is higher in osteolytic and bone marrow metastases compared to osteoblastic metastases. Information derived from [Ga]PSMA-PET and CT complement each other for the reliable diagnosis of the different types of bone metastases in PC patients.

Cited by 25 publications

References 43 publications

Exosomes derived from PC‑3 cells suppress osteoclast differentiation by downregulating miR‑148a and blocking the PI3K/AKT/mTOR pathway

Exosomes derived from PC‑3 cells suppress osteoclast differentiation by downregulating miR‑148a and blocking the PI3K/AKT/mTOR pathway

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

Contact Info

Product

Resources

About